At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
CJM112 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients
In Brief
A Phase 2 clinical trial evaluating CJM112 and Placebo for Hidradenitis Suppurativa (Acne Inversa). Completed, enrolled 66 participants across 16 sites in 5 countries.
Detailed Summary
This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to placebo. The study has two periods to explore preliminary dose effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa (Acne Inversa)
CountriesDenmark, Germany, Netherlands, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartApr 2015
First PostedApr 2015
Primary CompletionNov 2016
TodayJul 2026
First PostedApr 20, 2015
Enrollment StartApr 13, 2015
Primary CompletionNov 23, 2016
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.2 years ago
Interventions
CJM112biological
CJM112 Fully human IgG1 monoclonal antibody
Placebodrug